Literature DB >> 29434389

Outcomes From a Pharmacist - led Proton Pump Inhibitor Stewardship Program at a Single Institution.

Rebekah A Wahking1, Randal L Steele2, Rachel E Hanners2, Sean M Lockwood2,3, Kelly W Davis2.   

Abstract

Background: Proton pump inhibitors (PPIs) are effective medications for acid-related disorders; however, they are also overused and may be associated with several adverse effects. A PPI stewardship program was implemented at one institution to combat the overuse of PPIs. Objective: The purpose of this study is to evaluate the effectiveness of an inpatient PPI stewardship program in reducing PPI use, both during hospitalization and upon discharge.
Methods: This was a retrospective cohort study of all patients admitted to an internal medicine service at a single institution from March 14, 2016, to August 14, 2016, with an intervention by the PPI stewardship team. The primary objective was to determine the percentage of patients who tolerated inpatient and outpatient PPI discontinuation, or dose de-escalations upon discharge. Secondary objectives included the identification of risk factors for intolerance of PPI discontinuation, the occurrence of gastrointestinal (GI) complications after PPI discontinuation, and the percentage of patients who required "as needed" acid suppressive therapy (AST) with an antacid or histamine-2 receptor antagonist (H2RA) to control their symptoms while hospitalized.
Results: During the study time period, 537 patients with an active outpatient prescription for a PPI were admitted to an internal medicine team with 41.0% (n = 220) not meeting criteria for inpatient continuation. Of these patients, 95.9% (n = 211) tolerated inpatient PPI discontinuation, with 83.4% (n = 176) not requiring any "as needed" AST during hospitalization. Upon discharge, 57.1% patients (n = 24 of 42) tolerated PPI discontinuation at 3 months, while 81.8% patients (n = 18 of 22) tolerated PPI dose de-escalations at 3 months. Risk factors for intolerance of inpatient PPI discontinuation were a higher body mass index (BMI) (33.7 vs 30.3 kg/m2, P = .046) and longer length of stay (7.0 vs 4.0 days, P = .03), while longer duration of PPI use (9.0 vs 5.5 years, P = 0.03) was identified as a risk factor for intolerance of outpatient PPI discontinuation. One patient experienced reflux esophagitis 2 months after PPI discontinuation.
Conclusion: A PPI stewardship program at a single institution resulted in the reduction of inappropriate PPI use in both the inpatient and outpatient settings.

Entities:  

Keywords:  drug/medical use evaluation; gastrointestinal agents; physician prescribing

Year:  2017        PMID: 29434389      PMCID: PMC5805020          DOI: 10.1177/0018578717747192

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  38 in total

Review 1.  ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use.

Authors:  Neena S Abraham; Mark A Hlatky; Elliott M Antman; Deepak L Bhatt; David J Bjorkman; Craig B Clark; Curt D Furberg; David A Johnson; Charles J Kahi; Loren Laine; Kenneth W Mahaffey; Eamonn M Quigley; James Scheiman; Laurence S Sperling; Gordon F Tomaselli
Journal:  Am J Gastroenterol       Date:  2010-12       Impact factor: 10.864

2.  Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs.

Authors:  John M Inadomi; Lisa McIntyre; Latoya Bernard; A Mark Fendrick
Journal:  Am J Gastroenterol       Date:  2003-09       Impact factor: 10.864

3.  Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.

Authors:  Sandra Dial; J A C Delaney; Alan N Barkun; Samy Suissa
Journal:  JAMA       Date:  2005-12-21       Impact factor: 56.272

4.  Implementation of a proton pump inhibitor stewardship program.

Authors:  Kelly W Davis; Rachel E Hanners; Sean M Lockwood
Journal:  Am J Health Syst Pharm       Date:  2017-06-15       Impact factor: 2.637

5.  Imipramine for Treatment of Esophageal Hypersensitivity and Functional Heartburn: A Randomized Placebo-Controlled Trial.

Authors:  Julajak Limsrivilai; Phunchai Charatcharoenwitthaya; Nonthalee Pausawasdi; Somchai Leelakusolvong
Journal:  Am J Gastroenterol       Date:  2016-01-12       Impact factor: 10.864

6.  Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study.

Authors:  Brenda C T Kieboom; Jessica C Kiefte-de Jong; Mark Eijgelsheim; Oscar H Franco; Ernst J Kuipers; Albert Hofman; Robert Zietse; Bruno H Stricker; Ewout J Hoorn
Journal:  Am J Kidney Dis       Date:  2015-06-26       Impact factor: 8.860

7.  ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus.

Authors:  Nicholas J Shaheen; Gary W Falk; Prasad G Iyer; Lauren B Gerson
Journal:  Am J Gastroenterol       Date:  2015-11-03       Impact factor: 10.864

8.  Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals.

Authors:  Marcello Maggio; Andrea Corsonello; Gian Paolo Ceda; Chiara Cattabiani; Fulvio Lauretani; Valeria Buttò; Luigi Ferrucci; Stefania Bandinelli; Angela Marie Abbatecola; Liana Spazzafumo; Fabrizia Lattanzio
Journal:  JAMA Intern Med       Date:  2013-04-08       Impact factor: 21.873

9.  Defining Appropriate Use of Proton-Pump Inhibitors Among Medical Inpatients.

Authors:  Matt Pappas; Sanjay Jolly; Sandeep Vijan
Journal:  J Gen Intern Med       Date:  2015-11-09       Impact factor: 5.128

10.  The effects of guideline implementation for proton pump inhibitor prescription on two pulmonary medicine wards.

Authors:  E P M van Vliet; E W Steyerberg; H J A M Otten; A Rudolphus; P D Knoester; H C Hoogsteden; T van Gelder; P M J C Kuijpers; P D Siersema
Journal:  Aliment Pharmacol Ther       Date:  2008-10-22       Impact factor: 8.171

View more
  7 in total

1.  Guideline implementation is effective at reducing proton pump inhibitor use in hematology-oncology units: A multidisciplinary intervention for reducing Clostridioides difficile risk.

Authors:  Matthew J Ziegler; Craig Freyer; Daniel Landsburg; David Pegues; Warren Bilker; Rebecca Hirsh; Colleen Kucharczuk; Cheryl Gilmar; Theresa Gorman; Melissa Palmer; Christina Harker; Erin Lightheart; Jennifer H Han
Journal:  Infect Control Hosp Epidemiol       Date:  2019-08-30       Impact factor: 3.254

2.  Evaluation of a Pharmacist-Driven Protocol to Reduce Inappropriate Use of Acid-Suppressive Medications In the Non-ICU Setting.

Authors:  Tracey L Mersfelder; Chris Jacob; Jason K Lam; Kevin J Kavanaugh; Christin M Molnar
Journal:  P T       Date:  2019-08

3.  "Get Me Off This Medication!": A Comparison Between Gastroenterology and Primary Care Regarding Patient's Perceptions of Proton Pump Inhibitor Therapy.

Authors:  Raja Samir Khan; Yousaf Hadi; Swapna Gayam
Journal:  Cureus       Date:  2020-10-25

4.  Opportunities for successful de-escalation of proton pump inhibitors at a federally qualified health center.

Authors:  Joelle Ayoub; Jessina C McGregor; Rebecca M Castner; Harleen Singh
Journal:  BMC Pharmacol Toxicol       Date:  2021-04-16       Impact factor: 2.483

5.  Patients, Prescribers, and Institutional Factors Associated with Inappropriate Use of Acid Suppressive Therapy in Medical Wards: An Experience of a Single-Center in Saudi Arabia.

Authors:  Ghazwa B Korayem; Raghad Alkanhal; Raghad Almass; Sarah Alkhunaizan; Ghada Alharthi; Nader Bin Sheraim; Sara Alqahtani; Hadeel Alkofide
Journal:  Int J Gen Med       Date:  2021-08-30

6.  Feasibility of a pharmacy-led intervention to de-implement non-guideline-concordant proton pump inhibitor use.

Authors:  Jackson S Musuuza; Emily Fong; Paul Lata; Katie Willenborg; Mary Jo Knobloch; Margaret J Hoernke; Andrew R Spiel; Jessica S Tischendorf; Katie J Suda; Nasia Safdar
Journal:  Implement Sci Commun       Date:  2021-06-01

Review 7.  Deprescribing in older people.

Authors:  Michelle Liacos; Amy Theresa Page; Christopher Etherton-Beer
Journal:  Aust Prescr       Date:  2020-08-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.